Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

Prediction of antibody persistency from antibody titres to natalizumab

(2012) Poul Erik H Jensen et al.   Multiple Sclerosis Journal

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

(2011) Theo Rispens et al.   ANALYTICAL BIOCHEMISTRY

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differential effect of drug interference in immunogenicity assays

(2011) Margreet H. Hart et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing

(2011) Theo Rispens et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

(2011) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months

(2010) Begoña Oliver et al.   Multiple Sclerosis Journal

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

(2009) B. O. Khatri et al.   NEUROLOGY